Business Wire

CA-ALATION/BIGEYE/SODA

7.12.2021 15:02:09 CET | Business Wire | Press release

Share
Alation Forges Strategic Partnerships With Bigeye and Soda

Alation, Inc. , the leader in enterprise data intelligence solutions, today announced formal partnership agreements with Bigeye and Soda , leading data observability vendors. The partnerships provide customers with the choice to select the best data observability partner for their organisation’s needs.

Alation’s active data governance helps organisations drive data culture by providing all data users, regardless of technical skillset, with access to quality data. Bigeye’s data observability platform helps detect data quality issues and ensures reliable data pipelines. Soda’s data observability platform allows teams to discover, prioritise, and collaboratively resolve data issues. The platforms are invaluable for alerting technical users to deeper data quality issues, such as the trustworthiness of the data or its usability. Alation’s integrations with Bigeye and Soda provide all data consumers, from business users to data scientists, with a single-pane-of-glass view into the trustworthiness and reliability of data. This results in a streamlined analysis process that empowers data users to use data and generate insights with confidence.

“When it comes to data intelligence and data governance, Alation has long catered to the needs of every user, not just the technical user. Our customers see Alation as the primary source of reference for all metadata, which enables all teams across an organisation to make data-driven business decisions,” said Raj Gossain, Chief Product Officer, Alation. “The Alation Data Catalog is a platform known for its interoperability. With our APIs and partnerships, we continue to expand the ecosystem of companies that work with Alation, giving our customers a modern user experience that seamlessly integrates best-of-breed solutions that meet their needs.”

Fuelled by exponential data growth and expanding privacy regulations, data governance is a top priority for enterprises. Traditional approaches to data governance have long focused on restrictive data policies and procedures that hinder adoption and result in additional challenges for those responsible for the data. Effective data governance programs must focus on enabling users to leverage trusted, governed data to make informed, data-driven decisions. Organisations using an active, people-first approach to data governance, drive data culture and put quality data, not just any data, in everyone’s hands.

“A key part of ensuring data quality and reliable data pipelines is the ability to keep data teams and data consumers on the same page. With the integration between Alation and Bigeye, everyone — from data engineers all the way to business analysts — has a clear understanding of the health of the data,” said Egor Gryaznov, CTO and cofounder, Bigeye. “Pairing the leading data observability platform with Alation’s leading data catalog provides organisations with a holistic view of the quality of their data.”

“The modern data catalog is becoming a real-time, operational system that's deeply tied into an organisation’s data ecosystem. For metadata, that means it is purposefully built into every step of the data value chain, as opposed to it being an afterthought. This allows data teams to truly see what's happening so that they can catch data issues before they reach consumers downstream,” explains Maarten Masschelein, CEO and Co-Founder, Soda. “Through our partnership with Alation, users can discover and understand the data that matters to them, and trust they are working with data that is verified, reliable, and governed. Soda enables data producers and consumers to agree on what good data looks like by combining both machine learning-based alerting, as well as rules-based testing and validation of data. Every single operational metadata quality issue that Soda captures, can be made natively available in the Alation Data Catalog. We layer our data quality controls on top of Alation’s automated lineage to make it easy to do Root Cause Analysis (RCA), as well as assess the upstream and downstream impact of a data issue.”

To learn more about Alation’s partnerships with Bigeye and Soda:

About Alation
Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alation’s initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. More than 300 enterprises drive data culture, improve decision making, and realise business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazine’s Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com .

About Bigeye
Bigeye is the leading data observability platform designed to help data teams build trust in data. Data teams use Bigeye to instrument their data with monitoring, detect anomalies, and publish SLAs for their stakeholders to know the health of the data at all times and ensure reliable data pipelines. Complete API access, a user-friendly interface, and flexible customisation options help data teams work the way they want to. Bigeye can be deployed in as little as 15 minutes and uses automation and anomaly detection to help teams monitor all aspects of their data quality, proactively detect and resolve issues, and ensure that every user can trust the data. www.bigeye.com

About Soda
Soda is the data monitoring platform that keeps your data fit for purpose, verifiable and trustworthy. We uncover data issues, alert the right teams, and trigger resolution workflows to identify causes that impede data quality. Our open source testing projects and monitoring platform brings together data engineers, operations and the business to create trusted data. Data-driven organisations choose Soda to realise the value of their data and secure its quality. For more information, visit www.soda.io .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 08:00:00 CET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 08:00:00 CET | Press release

Breakthrough designation means Cognita™ will engage in prioritized interaction with FDA regarding clearance of device designed to help solve the radiology capacity bottleneck Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 08:00:00 CET | Press release

Cielo, one of Brazil’s leading payment service providers, is piloting remote connectivity management for its point-of-sale (POS) terminals across the country, in partnership with Thales. By deploying Thales’s eSIM connectivity management platform based on the latest GSMA SGP.32 IoT standard, Cielo is accelerating its transition from manual, on-site SIM management to fully remote, secure and resilient connectivity. For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network op

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 08:00:00 CET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 07:00:00 CET | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new produ

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye